

Supplementary Table 1. Baseline demographic and clinical characteristics of PD patients (*n* = 30)

Variables	Values
Age at onset, yr	51.1 ± 8.0
PD duration, yr	9.6 ± 2.1
Amantadine therapy duration, yr	7.9 ± 1.1
Sex (M:F)	11:19
LEDD, mg/d	934.8 ± 340.4
Amantadine daily dose, mg/d	293.3 ± 43.0
K-MoCA	25.9 ± 3.5
MDS-UPDRS Part I	7.3 ± 5.1
MDS-UPDRS Part II	6.1 ± 4.7
MDS-UPDRS Part III	28.9 ± 13.4
Motor fluctuation (Yes:No)	3:27
Dyskinesia (Yes:No)	3:27
Hoehn-Yarr stage	2.0 ± 0.5
NMSS	20.9 ± 17.9
PDQ-39-SI	4.7 ± 5.7

Values are presented as mean ± standard deviation unless otherwise indicated. PD, Parkinson's Disease; M, male; F, female; LEDD, levodopa equivalent daily dose; K-MoCA, Korean Version of Montreal Cognitive Assessment; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; NMSS, Nonmotor Symptom Scale; PDQ-39-SI, Parkinson's Disease Questionnaire 39 summary index.